PMID- 32173028
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 81
IP  - 6
DP  - 2020 Jun
TI  - New genetic predictors for abacavir tolerance in HLA-B*57:01 positive 
      individuals.
PG  - 300-304
LID - S0198-8859(19)31410-7 [pii]
LID - 10.1016/j.humimm.2020.02.011 [doi]
AB  - Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage 
      of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive 
      value for the development of ABC HSS. However, 45% of individuals who carry 
      HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes 
      in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine 
      other factors required for the development of ABC HSS. Assignment of phenotype 
      showed that ABC HSS subjects were significantly less likely than tolerants to 
      carry only ERAP1 hypoactive trimming allotypes (p = 0.02). An altered 
      self-peptide repertoire model by which abacavir activates T cells is in keeping 
      with observation that endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes 
      that favour efficient peptide trimming are more common in ABC HSS patients 
      compared to patients who tolerate ABC. Independently, non-specific immune 
      activation via soluble cluster of differentiation antigen 14 (sCD14) may also 
      influence susceptibility to ABC HSS.
CI  - Copyright (c) 2020 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Pavlos, Rebecca
AU  - Pavlos R
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Telethon Kids Institute, Western Australia, Australia.
FAU - Deshpande, Pooja
AU  - Deshpande P
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; School of Human Sciences, University of Western Australia, 
      Western Australia, Australia.
FAU - Chopra, Abha
AU  - Chopra A
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - Leary, Shay
AU  - Leary S
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - Strautins, Kaija
AU  - Strautins K
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - Nolan, David
AU  - Nolan D
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Department of Clinical Immunology, Royal Perth Hospital, 
      Western Australia, Australia.
FAU - Thorborn, Daren
AU  - Thorborn D
AD  - Celgene Corporation, NJ, USA.
FAU - Shaefer, Mark
AU  - Shaefer M
AD  - ViiV Healthcare at Research Triangle Park, NC, USA.
FAU - Rauch, Andri
AU  - Rauch A
AD  - Inselspital, Bern, Switzerland.
FAU - Dunn, David
AU  - Dunn D
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - Montaner, Julio
AU  - Montaner J
AD  - British Columbia Centre for Excellence in HIV/AIDS, Vancouver British Columbia, 
      Canada.
FAU - Rachlis, Anita
AU  - Rachlis A
AD  - Sunnybrook Health Sciences Centre, Toronto, Canada; University of 
      Toronto,Toronto, Canada.
FAU - Almeida, Coral-Ann
AU  - Almeida CA
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Department of Haematology, Fiona Stanley Hospital, Western 
      Australia, Australia.
FAU - Choo, Linda
AU  - Choo L
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - James, Ian
AU  - James I
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia.
FAU - Redwood, Alec J
AU  - Redwood AJ
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Institute for Respiratory Health, University of Western 
      Australia, Western Australia, Australia.
FAU - Li, Yueran
AU  - Li Y
AD  - School of Human Sciences, University of Western Australia, Western Australia, 
      Australia.
FAU - Gaudieri, Silvana
AU  - Gaudieri S
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; School of Human Sciences, University of Western Australia, 
      Western Australia, Australia; Vanderbilt University Medical Centre, Nashville, 
      USA.
FAU - Mallal, Simon A
AU  - Mallal SA
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Vanderbilt University Medical Centre, Nashville, USA.
FAU - Phillips, Elizabeth J
AU  - Phillips EJ
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Western 
      Australia, Australia; Vanderbilt University Medical Centre, Nashville, USA. 
      Electronic address: elizabeth.j.phillips@vumc.org.
LA  - eng
GR  - R01 HG010863/HG/NHGRI NIH HHS/United States
GR  - UM1 AI068634/AI/NIAID NIH HHS/United States
GR  - F30 AI131780/AI/NIAID NIH HHS/United States
GR  - P50 GM115305/GM/NIGMS NIH HHS/United States
GR  - P30 AI110527/AI/NIAID NIH HHS/United States
GR  - R21 AI139021/AI/NIAID NIH HHS/United States
GR  - R34 AI136815/AI/NIAID NIH HHS/United States
GR  - UM1 AI068636/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20200312
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Allergens)
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - EC 3.4.11.- (Aminopeptidases)
RN  - EC 3.4.11.- (ERAP1 protein, human)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Allergens/immunology
MH  - Aminopeptidases/genetics
MH  - Anti-HIV Agents/immunology/*therapeutic use
MH  - Dideoxynucleosides/adverse effects/immunology/*therapeutic use
MH  - Drug Hypersensitivity Syndrome/etiology/*genetics
MH  - Drug-Related Side Effects and Adverse Reactions/*genetics
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HIV Infections/complications/*drug therapy
MH  - HIV-1/*physiology
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Lipopolysaccharide Receptors/genetics
MH  - Male
MH  - Minor Histocompatibility Antigens/genetics
MH  - Phenotype
MH  - Retrospective Studies
PMC - PMC7266722
MID - NIHMS1590559
OTO - NOTNLM
OT  - Abacavir hypersensitivity syndrome
OT  - Endoplasmic reticulum aminopeptidase 1
OT  - Human leukocyte antigen
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/03/17 06:00
MHDA- 2021/02/20 06:00
PMCR- 2020/06/03
CRDT- 2020/03/17 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/03/17 06:00 [entrez]
PHST- 2020/06/03 00:00 [pmc-release]
AID - S0198-8859(19)31410-7 [pii]
AID - 10.1016/j.humimm.2020.02.011 [doi]
PST - ppublish
SO  - Hum Immunol. 2020 Jun;81(6):300-304. doi: 10.1016/j.humimm.2020.02.011. Epub 2020 
      Mar 12.